Yttriga

RSS

yttrium [90Y] chloride

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Yttriga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Yttriga.

This EPAR was last updated on 14/08/2014

Authorisation details

Product details
Name
Yttriga
Agency product number
EMEA/H/C/000596
Active substance
yttrium [90Y] chloride
International non-proprietary name (INN) or common name
yttrium [90Y] chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
V09
Publication details
Marketing-authorisation holder
Eckert Ziegler Radiopharma GmbH
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
19/01/2006
Contact address
Robert-Rossle-Str. 10
D-13125 Berlin
Germany

Product information

21/07/2014 Yttriga - EMEA/H/C/000596 - IAIN/0013

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

DIAGNOSTIC RADIOPHARMACEUTICALS

Therapeutic indication

To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Radiopharmaceutical precursor - Not intended for direct use in patients.

Assessment history

How useful was this page?

Add your rating